RTP Mobile Logo
Select Publications

Johann de Bono, MBChB, MSc, PhD

Abida W et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 2020;38(32):3763-72. Abstract

de Bono J et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020;382(22):2091-102. Abstract

de Bono J et al. TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA). J Clin Oncol 2020;38(15):5566. Abstract

de Wit R et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019;381(26):2506-18. Abstract

Hussain M et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 2020;383(24):2345-57. Abstract

Mateo J et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): A multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020;21(1):162-74. Abstract

Mateo J et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015;373(18):1697-708. Abstract

Paschalis A, de Bono JS. Prostate cancer 2020: "The Times They Are a'Changing". Cancer Cell 2020;38(1):25-7. Abstract

Zafeirou Z et al. Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency. European Urol 2019;75(1):184-92. Abstract

Charles J Ryan, MD

Boevé LMS et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: Data from the HORRAD trial. Eur Urol 2019;75(3):410-8. Abstract

Fendler WP et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 2019;25(24):7448-54. Abstract

Fizazi K et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380(13):1235-46. Abstract

Ke X et al. Treatment patterns in men with metastatic castration sensitive prostate cancer (mCSPC) in the United States (US). ASCO 2020;Abstract e19131.

Shore N et al. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: Results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol 2019;14(5):527-39. Abstract

Smith MR et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379(9810):39-46. Abstract

VanderWeele DJ et al. Metastatic hormone-sensitive prostate cancer: Clinical decision making in a rapidly evolving landscape of life-prolonging therapy. J Clin Oncol 2019;37(32):2961-7. Abstract